Rho Chi Post

An award-winning, electronic, student-operated newsletter publication by the St. John's University College of Pharmacy and Health Sciences Rho Chi Beta Delta chapter

Menu

Skip to content
  • Home
  • Issues
    • Current Issue
    • All Issues
  • Articles
    • Featured
    • In the News / Politics
    • Events
    • Clinical
    • Advice / Opinions
    • Puzzles
    • Recently in PubMed
  • For Authors
    • Author Guidelines
    • AMA Citation Generator
    • Sign Up for Article(s)
    • Suggest Article(s)
    • Submit Article(s)
    • Check Statuses
    • Cite Your Article
  • About Us
    • About the Rho Chi Post
    • The Editorial Team
  • Apply for a Position
  • Subscribe
  • Login

United States maternal mortality crisis: A new approach

By: Yeonah Suk, PharmD Candidate c/o 2020 Of all the industrialized countries in the world, the United States (US) still ranks number one in having the highest rate of maternal mortality. Data from the World Health Organization demonstrates that overused procedures including early labor induction, restricting food and drink, as well as mandating bed rest…

Continue reading →

Challenging the stigma of mental health

By: Mah Noor, PharmD Candidate c/o 2021 As society flourishes, life seems to grow more complex. Among the barrage of images, voices and social media campaigns, a domestic issue which often seems to be neglected in the United States is the overall deficit in addressing various aspects of mental health. On May 30, 2018 The…

Continue reading →

Treatment of initial and recurrent Clostridium difficile colitis

By: Joseph Eskandrous, PharmD Candidate c/o 2019 Clostridium difficile (C. difficile) is a gram-positive, anaerobic, sporogenic bacterium that is primarily responsible for antibiotic-associated diarrhea and is a significant nosocomial pathogen.1 Clostridium difficile infection (CDI) is triggered by toxin production from the bacteria. Normal bacterial flora is disrupted when the colon is colonized with C. difficile…

Continue reading →

Food and Drug Administration (FDA) approves baloxavir marboxil (XOFLUZATM): first new flu drug in 20 years

By: Ruchira Kasbekar, PharmD Candidate c/o 2020 It is estimated that approximately 80,000 Americans died from the flu during the 2017-2018 flu season which is the highest death toll from influenza in the last four decades.1 As the 2017-2018 flu season progressed, there was a shortage of oseltamivir (Tamiflu®) availability. To prevent shortages during the…

Continue reading →

Targeting biomarkers in immuno-oncology: current agents and its clinical impact

By: Jonathan Mercado (PharmD Candidate c/o 2019), Rebecca Sin (PharmD Candidate c/o 2019) Immuno-oncology is an advanced and rapidly growing area of research focused on utilizing the body’s immune system to help fight cancer. Immunotherapy has demonstrated clinical efficacy and unprecedented rates of response in treating specific cancers, usurping the classical approach to chemotherapy and…

Continue reading →

(Volume 8, Issue 3)
Challenging the stigma of mental health

Treatment of initial and recurrent Clostridium difficile colitis

United States maternal mortality crisis: A new approach

View Full Issue

Do You Want to be a Published Author? Submit your Article(s) Today!


 Tweets by @RhoChiPost
HOME: Home Page

ISSUES: Volume 8 . Volume 7 . Volume 6 . Volume 5 . Volume 4 . Volume 3 . Volume 2 . Volume 1

ARTICLES: Featured . In the News / Politics . Events . Clinical . Advice / Opinions . Puzzles

FOR AUTHORS: Guidelines . Writing Deadlines . AMA Citation Generator . Sign Up . Suggest . Submit . Cite

ABOUT US: About the Rho Chi Post . The Editorial Team . Apply for a Position

SUBSCRIBE: Google Groups Email List

Translate:
Copyright © 2011-2019 Rho Chi Post